Fig. 4From: Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trialBiological changes induced by each treatment at week 3 compared to baseline of selected genes and gene signaturesBack to article page